Pacific Shuanglin Bio-pharmacy was warned by the Shanxi Securities Regulatory Commission for signing a supplementary agreement with clients without filing it.

①Pacific Shuanglin Bio-pharmacy's subsidiary signed supplementary agreements and memorandums with clients regarding certain sales matters that included liability clauses, but these were not incorporated into the company's internal control management system, resulting in inaccurate disclosure and a penalty; ②Previously, JiMin Health was also forced to correct its performance due to supplementary agreements signed during sales.

cls.cnMay 11 19:47

Pacific Shuanglin Bio-pharmacy (000403.SZ): received the decision letter on administrative regulatory measures from the Shanxi Securities Regulatory Bureau.

On May 11, Gelonghui reported that Pacific Shuanglin Bio-pharmacy (000403.SZ) announced that it recently received the "Decision on Ordering Pacific Shuanglin Bio-pharmacy Co., Ltd. to Make Corrections" ([2025] No. 18) and the "Decision on Issuing Warning Letters to Li Hao, Rong Xian Kui, Zhao Yu Lin, Fu Shao Lan, and Yuan Hua Gang" ([2025] No. 19) issued by the Shanxi Regulatory Bureau of the China Securities Regulatory Commission.

Gelonghui FinanceMay 11 16:36

Express News | DeepSeek released the Prover-V2 model, with a parameter count reaching 671 billion.

BreakingsApr 30 18:36

Express News | Pacific Shuanglin Bio-pharmacy: The slurry volume is expected to increase by over 20% year-on-year in 2025.

BreakingsApr 30 11:46

Pacific Shuanglin Bio-pharmacy (000403): The volume of plasma collection continues to grow significantly, and capacity expansion will help release performance in the later period.

Short-term production halts led to a reduction in supply, resulting in a temporary decline in performance for Q1 2025. In 2024, the company achieved revenue of 2.655 billion yuan (+14.00%) and a net income attributable to the parent company of 0.745 billion yuan (+21.76%), excluding non-recurring items.

China Postal SecuritiesApr 29 19:02

Revenue Miss: Pacific Shuanglin Bio-pharmacy Co., LTD Fell 6.2% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models

Simply Wall StApr 26 07:46